Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.66 USD | +3.87% | +0.90% | +36.14% |
Business Summary
Number of employees: 187
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Small Molecule Therapeutics
100.0
%
| 47 | 100.0 % | 79 | 100.0 % | +67.84% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 47 | 100.0 % | 79 | 100.0 % | +67.84% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Nello Mainolfi
FOU | Founder | 45 | 01/15/01 |
Bruce Jacobs
DFI | Director of Finance/CFO | 54 | 15/19/15 |
Juliet Williams
CTO | Chief Tech/Sci/R&D Officer | - | 05/21/05 |
Kevin Dushney
CTO | Chief Tech/Sci/R&D Officer | - | 03/21/03 |
Jared Gollob
CTO | Chief Tech/Sci/R&D Officer | 60 | 01/18/01 |
Vijay Sabesan
CTO | Chief Tech/Sci/R&D Officer | 51 | 06/21/06 |
Jeremy Chadwick
COO | Chief Operating Officer | 61 | 22/23/22 |
Investor Relations Contact | - | 01/23/01 | |
Aimee Mishkin
LAW | General Counsel | - | 01/20/01 |
Melissa Brody
PRN | Corporate Officer/Principal | - | 02/21/02 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | 28/03 |
Joanna Horobin
BRD | Director/Board Member | 69 | 01/18/01 |
John Maraganore
BRD | Director/Board Member | 60 | 17/22/17 |
Elena Ridloff
BRD | Director/Board Member | 44 | 12/21/12 |
Bruce Booth
FOU | Founder | 49 | 01/16/01 |
Pamela Esposito
BRD | Director/Board Member | 50 | 04/20/04 |
Jeffrey Albers
BRD | Director/Board Member | 52 | 01/20/01 |
Victor Sandor
BRD | Director/Board Member | 57 | 03/22/03 |
Nello Mainolfi
FOU | Founder | 45 | 01/15/01 |
Director/Board Member | 35 | 01/20/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 61,111,678 | 60,515,185 ( 99.02 %) | 0 | 99.02 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.14% | 2.05B | |
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |
- Stock Market
- Equities
- KYMR Stock
- Company Kymera Therapeutics, Inc.